24.Jul.2017-Expires: 7 days - Do not archive

Acetaminophen

Acetaminophen
24.Jul.2017-Expires: 7 days - Do not archive

DESCRIPTION

SUBSTANCE NAME

Acetaminophen (Paracetamol)
 

SUBSTANCE CLASS

Para-Aminophenol Derivative

INTERVENTION CRITERIA

Intervention Level

Acute Exposure

 
Ingestion
 
Aged 6 years or under ingesting
- 200 mg/kg acetaminophen (paracetamol) or more over a period of less than 8 hours
 
For obese children, the weight used should be based on ideal body weight.
 
Aged older than 6 years ingesting
- At least 10 g or 200 mg/kg (which ever is lower) over a period of less than 8 hours
- Exposures with intent to self-harm
 
For obese children, the weight used should be based on ideal body weight.
 
Also investigate if:
- The dose or timing of ingestion is uncertain, or;
- The patient is symptomatic
 

Time of Ingestion Unknown

If the time of ingestion is unknown and the dose is above the acute intervention level or unknown: commence an acetylcysteine infusion and investigate.
 

Supratherapeutic Exposure

 
Ingestion
Aged 6 years or under ingesting
- 200 mg/kg acetaminophen (paracetamol) or more over a single 24-hour period;
- 150 mg/kg or more per 24-hour period for the preceding 48 hours;
- 100 mg/kg or more per 24-hour period for more than 48 hours.
 
For obese children, the weight used should be based on ideal body weight.
 
Aged older than 6 years ingesting
- At least 10 g or 200 mg/kg (whichever is less) over a single 24-hour period;
- At least 6 g or 150 mg/kg (whichever is less) per 24 hour period for the preceding 48 hours;
- More than 4 g per day or 100 mg/kg (whichever is less) per 24-hour period for more than 48 hours in those who also have symptoms indicating possible liver injury (e.g. abdominal pain, nausea or vomiting)
- Exposures with intent to self-harm.
 
For obese children, the weight used should be based on ideal body weight.
 
Also investigate if:
- The dose or timing of ingestion is uncertain
- The patient is symptomatic
 

Investigation and Initial Management

Acute Ingestion

 
 
Decontamination
 
Administer activated charcoal to co-operative adults if within 2 hours of overdose of immediate release solid formulations or within 4 hours for modified release solid formulations.[1]
 
2 to 8 hours post-ingestion
 
Ingestion by children < 6 years of age of liquid acetaminophen (paracetamol)
                                                                                                             
Measure:
Serum acetaminophen (paracetamol) concentration at least 2 hours post-ingestion:[1]
 
- If this concentration is less than 1,000 umol/L (150 mg/L) the child may safely be discharged. Otherwise, repeat the measurement at 4 hours and if above the paracetamol treatment nomogram line administer acetylcysteine.
 
Ingestion of standard release or liquid formulations
 
Measure:
Serum acetaminophen (paracetamol) concentration at least 4 hours and within 8 hours post-ingestion, and plot against the paracetamol treatment nomogram:[1]
 
- If this concentration is below the nomogram line, the patient does not require acetylcysteine;
- If this concentration is above the nomogram line, immediately commence a full course of acetylcysteine;
- If this concentration will not be available within 8 hours of ingestion, immediately commence a full course of acetylcysteine. This treatment can then be halted if the result subsequently returns below the nomogram line.
 
Ingestion of modified release formulations
 
If the ingestion is above the intervention level, immediately commence a full course of acetylcysteine, then:[1]
 
Measure:
Serum acetaminophen (paracetamol) concentration at least 4 hours post-ingestion and a second concentration 4 hours following the first:
 
- If these concentrations are both below the paracetamol treatment nomogram line, and the second concentration less than the first, the acetylcysteine infusion may be halted. Otherwise, the full treatment course must be completed.
 
8 to 24 hours post-ingestion
 
Immediately commence a acetylcysteine infusion, then
 
Measure:
Serum acetaminophen (paracetamol) concentration
Alanine aminotransferase (ALT)
 
- If the serum acetaminophen (paracetamol) concentration is below the paracetamol treatment nomogram line and the ALT is less than 50 U/L, then the acetylcysteine infusion can be halted and no further medical treatment is necessary.[1]
- If the serum acetaminophen (paracetamol) concentration is above the paracetamol treatment nomogram line or the ALT greater than 50 U/L, then complete a full course of acetylcysteine.[1]
 
If ALT is greater than 50 U/L then also measure:
BUN (Urea)
Creatinine
Electrolytes
Blood sugar
Phosphate
Venous Blood Gas (pH and lactate in particular)
 
24 plus hours post-ingestion, or time of ingestion unknown
 
Immediately commence a acetylcysteine infusion, then
 
Measure:
Serum acetaminophen (paracetamol) concentration
Alanine aminotransferase (ALT)
International Normalized Ratio (INR)
 
- If the serum acetaminophen (paracetamol) concentration is less than 66 umol/L (10 mg/L) and the ALT is less than 50 U/L, then the infusion can be halted and no further medical treatment is necessary.[1]
- If the serum acetaminophen (paracetamol) concentration is greater than 66 umol/L (10 mg/L) or the ALT is greater than 50 U/L, then complete the full course of acetylcysteine.[1]
 
If ALT is greater than 50 U/L then also measure:
BUN (Urea)
Creatinine
Electrolytes
Blood sugar
Phosphate
Venous Blood Gas (pH and lactate in particular)
 

Supratherapeutic Exposure

 
In patients meeting intervention criteria for supratherapeutic ingestion
 
Measure:
Serum acetaminophen (paracetamol) concentration
Alanine aminotransferase (ALT)
 
-If serum acetaminophen (paracetamol) is < 132 umol/L (< 20 mg/L) and ALT < 50 U/L, then no medical treatment is necessary.[1]
-If serum acetaminophen (paracetamol) is > 132 umol/L (> 20 mg/L) or ALT > 50 U/L, then commence an acetylcysteine infusion.[1]
 
After commencement of the infusion measure serum acetaminophen (paracetamol) and ALT concentrations 8 hours after the previous measurement.
-If serum acetaminophen (paracetamol) is < 66 umol/L (< 10 mg/L) and ALT < 50 U/L, then the infusion can be halted and no further medical treatment is necessary.[1]
 
Otherwise continue the infusion and check serum acetaminophen (paracetamol) and ALT at 12 hourly intervals until:
-Serum acetaminophen (paracetamol) is < 66 umol/L (< 10 mg/L) and ALT < 50 U/L, then the infusion can be halted and no further medical treatment is necessary.[1]
 

Observation Period

Observation at Home

No observation is required for those patients with ingested doses or serum acetaminophen (paracetamol) determinations below the intervention levels. However, review is warranted should nausea, vomiting, or abdominal pain occur after discharge, particularly if within 24 to 48 hours after the ingestion.
 

Medical Observation

Medical observation of asymptomatic patients is not required provided serum acetaminophen (paracetamol) investigation is undertaken and the concentration is below the appropriate intervention level.
 

Admission Criteria

Patients requiring intervention for acute acetaminophen (paracetamol) overdose should be appropriately decontaminated and managed in a medical facility able to rapidly determine serum acetaminophen (paracetamol) and provide acetylcysteine.
 
Referral to an intensive care unit and/or liver transplant unit may be required in severe poisoning.
 

TREATMENT

TREATMENT SUMMARY

Decontamination with activated charcoal is recommended in cooperative adults within 2 hours of ingestion of (solid) immediate-release forms, or within 4 hours of ingestion of either modified-release forms or greater than 30 g of acetaminophen (paracetamol).[2][1]
 
Following acute overdose, assessment of serum acetaminophen (paracetamol) concentration between 4 to 8 hours and use of the paracetamol treatment nomogram is necessary to determine requirement for the antidote acetylcysteine. If a result is not available within this timeframe acetylcysteine should be commenced and is considered beneficial at any time post-ingestion.[3] Acetylcysteine administration following supratherapeutic/chronic ingestions is dependent on dose and investigations.
 
In cases of massive acetaminophen (paracetamol) ingestion (greater than 50 g or serum concentrations greater than twice the nomogram line) doubling the final (16 hour) acetylcysteine infusion is recommended.[1] Hemodialysis may be beneficial in severe poisoning with very high blood concentrations and particularly if acetylcysteine is unavailable.[4]
 
Supportive care includes the continued use of acetylcysteine, monitoring of major organ function, and further management as indicated. Use of sedating drugs is not recommended due to their impact on the assessment of mental function/encephalopathy. Acute hepatic and renal failure are well recognized concerns. Most complications are a consequence of hepatic failure and rarely occur in its absence.
 
Advice should be sought from a specialist liver transplant unit:[1]
If 
The International Normalized Ratio (INR) is greater than 3 at 48 hours or 4.5 at any time after overdose
Or
Oliguria or creatinine is greater than 200 umol/L (2.2 mg/dL)
Or
Persistent acidosis (pH less than 7.3) or arterial lactate greater than 3 mmol/L
Or
Systolic hypotension with a blood pressure less than 80 mmHg, despite resuscitation
Or
Hypoglycemia
Or
Severe thrombocytopenia
Or
Encephalopathy of any degree, or any alteration of consciousness (Glasgow Coma Scale less than 15) not associated with co-ingestion of sedatives
 
Early discussion with a liver transplant unit is essential. Advice may be given and a decision to transport dependent upon results. In general it is considered desirable to transport patients prior to development of grade 2 encephalopathy.
 
Emergency Stabilization
Emergency stabilization should not be required
Decontamination
Single dose activated charcoal
Antidote(s)
Acetylcysteine
Enhanced Elimination
Hemodialysis
Supportive Care
Monitoring
Hepatic
Acute hepatic failure
Renal
Acute renal failure
Metabolic
Metabolic acidosis
Hypoglycemia
Hypophosphatemia
Cardiovascular
Hypotension
Cardiotoxicity
Hematologic
Coagulopathy
Thrombocytopenia
Hemolysis
Respiratory
Pulmonary edema
Gastrointestinal
Pancreatitis
 

EMERGENCY STABILIZATION

Emergency Stabilization Should Not Be Required

Emergency stabilization of patients following recent ingestion of acetaminophen (paracetamol), solely, is highly unlikely to be necessary. However, massive overdose may lead to early decline in level of consciousness and/or lactic acidosis.[5] Immediate attention should be given to the airways, assessment of blood glucose, and supportive care.[1] Definitive treatment is provided by the antidote acetylcysteine, with hemodialysis possibly indicated.[4] Carefully consider coingestant(s) or non-toxicological causes.
 

DECONTAMINATION

Ingestion

Single Dose Activated Charcoal

Gastrointestinal decontamination is not indicated in any pediatric (< 6 years old) patient following acetaminophen (paracetamol) overdose.[1]
 
Gastrointestinal decontamination with activated charcoal is only indicated:[1]
In co-operative adult patients
If the formulation is a solid (e.g. tablets, capsules)
If at least 10 g or 200 mg/kg (which ever is lower) is ingested
Within 2 hours of the overdose for standard release formulations
Within 4 hours of the overdose for modified release formulations (patients may benefit from activated charcoal beyond 4 hours following large ingestions)
If at least 30 g is ingested
Within 4 hours of the overdose for standard release formulations
 
Further decontamination with activated charcoal may be necessary for co-ingestants.
 
Induction of emesis and gastric lavage are both contra-indicated.
 
Single dose activated charcoal[6]
CHILD
1 to 2 g/kg orally
ADULT
50 to 100 g orally
 

ANTIDOTE(S)

Acetylcysteine

Acetylcysteine is the treatment of choice for acetaminophen (paracetamol) overdose, and its intravenous use considered preferable.[7] When administered within eight hours of acetaminophen (paracetamol) ingestion it is almost completely effective in preventing death.[8] Use beyond this time is also beneficial and recommended.[3]
 
In the case of modified release formulations, acetylcysteine may need to be continued after the initial 21 hour infusion.
 

Indications

Intra-venous acetylcysteine infusion is indicated as outlined in the following links:
 
 
 

Dose and Administration

While acetylcysteine is recommended to be administered intravenously in 5% dextrose in water, 1/2 normal (0.45%) saline may be substituted if necessary.[9] It is recommended that acetylcysteine dose for adults be calculated for actual body weight rounded up to the nearest 10 kg with a ceiling weight of 110 kg.[1]
 
CHILD
 
Children 20 kg or less body weight:[1]
150 mg/kg in 3 mL/kg of 5% dextrose over 60 minutes
Followed by 50 mg/kg in 7 mL/kg of 5% dextrose over 4 hours
Followed by 50 mg/kg in 7 mL/kg of 5% dextrose over 8 hours
Followed by 50 mg/kg in 7 mL/kg of 5% dextrose over 8 hours
 
Children > 20 kg body weight:[1]
150 mg/kg in 100 mL of 5% dextrose over 60 minutes
Followed by 50 mg/kg in 250 mL of 5% dextrose over 4 hours
Followed by 50 mg/kg in 250 mL of 5% dextrose over 8 hours
Followed by 50 mg/kg in 250 mL of 5% dextrose over 8 hours
 
Closely monitor fluid and electrolyte balance.
 
ADULT
 
Administer:[1]
150 mg/kg in 200 mL diluent IV over 60 minutes
Followed by 50 mg/kg in 500 mL diluent IV over 4 hours
Followed by 100 mg/kg in 1,000 mL diluent over 16 hours
 
 
In the case of massive overdose (those whose acetaminophen (paracetamol) concentration is more than double the nomogram line) it is recommended that the final infusion over 16 hours is doubled to 200 mg/kg.[1]
 

Antidote Endpoint

Acute
Recommended investigations according to time from acetaminophen (paracetamol) ingestion to acetylcysteine treatment[1]
 
Time (hours) from ingestion to start of acetylcysteine
Investigations on admission
Investigations at the completion of acetylcysteine
Less than 8 hours
Serum acetaminophen (paracetamol) concentration
Nil*
8 to 24 hours
Serum acetaminophen (paracetamol) concentration and ALT
ALT, UEC*
Greater than 24 hours
Serum acetaminophen (paracetamol) concentration, ALT and INR
ALT, INR, UEC
Patients with an ALT > 50 U/L
UEC, LFTs, INR, BSL, serum phosphate, blood gas (pH and lactate)
Repeat investigations 12 hourly including: UEC, LFTs, INR, BSL, serum phosphate, VBG
ALT = alanine aminotransferase; BSL = blood sugar level; UEC = BUN (urea), electrolytes, and creatinine; LFTs = liver function tests; VBG = venous blood gases including pH and lactate.
 
* NOTE: If symptoms of hepatotoxicity (e.g. nausea, vomiting, abdominal pain or tenderness) then repeat ALT. Or if initial concentration more than double the nomogram line, then repeat ALT and paracetamol concentration at the completion of acetylcysteine.
 
Patients who have ALT > 50 U/L following completion of initial acetylcysteine require acetylcysteine to be continued at the rate of the last infusion stage (100 mg/kg acetylcysteine over 16 hours or 150 mg/kg/24 hours).[1]
 
Continue acetylcysteine until the patient is clinically improving, ALT is decreasing, INR is improving and < 2, and the acetaminophen (paracetamol) concentration is less than 66 umol/L (10 mg/L).[1][10]
 
Chronic
Following chronic ingestion of acetaminophen (paracetamol) and commencement of acetylcysteine infusion, measure serum acetaminophen (paracetamol) and ALT concentrations 8 hours after the previous measurement.
If serum acetaminophen (paracetamol) is <66 umol/L (<10 mg/L) and ALT is less than 50 U/L, then the infusion can be halted and no further medical treatment is necessary.[1]
 
Otherwise continue the infusion and check serum acetaminophen (paracetamol) and ALT at 12 hourly intervals until:
Serum acetaminophen (paracetamol) is <66 umol/L (<10 mg/L) and ALT is less than 50 U/L, then the infusion can be halted and no further medical treatment is necessary.[1]
 

Precautions

Pregnancy
Acetylcysteine should be administered to pregnant patients following the standard adult regimen. Transplacental transport of acetylcysteine is not thought to be clinically significant,[11] however, delay in initiation of acetylcysteine treatment is associated with increased incidence of spontaneous abortion and fetal death.[12] Acetylcysteine is not considered teratogenic.[13]
 

Adverse Effects

Anaphylactoid Reaction
Six to 23% of patients receiving IV acetylcysteine develop an anaphylactoid reaction.[14][15] These do not represent an immunological (allergic) reaction; rather, they are thought due to a direct dose-dependent effect on histamine release and generally occur within the first two hours of an infusion.
 
History of previous anaphylactoid reaction to acetylcysteine does not contraindicate use. If there is concern of recurrence of the reaction the patient may be pre-treated 15 minutes before commencement of the infusion with an antihistamine.[16]
 
Effects range from mild flushing to urticaria, angioedema, or bronchospasm. Hypotension may occasionally occur. Asthmatics appear more at risk. However, effects are usually easily managed and there is no reason to withhold acetylcysteine from any patient when indicated.[16]
 
Hyponatremia
Hyponatremia has been reported in children if administered acetylcysteine in 5% dextrose following adult protocols for dilution of infused dose.[17]
 
INR
Increased International Normalized Ratio (INR) in the absence of acetaminophen-induced hepatic injury is relatively common.[18][19][20] It is important that increased INR alone (below 2) is not misinterpreted as evidence of acetaminophen-induced hepatic injury, as this may lead to unnecessarily prolonged acetylcysteine administration.[19]
 

ENHANCED ELIMINATION

Hemodialysis

In the majority of cases NAC is the only specific treatment required as acetaminophen (paracetamol) has a high endogenous clearance. However, acetaminophen (paracetamol) is moderately dialyzable,[21][22][23] and extracorporeal techniques may be beneficial in excessively large overdoses if NAC cannot be administered or where there is mitochondrial paralysis or other signs of severe poisoning.
 
Intermittent hemodialysis is recommended in any of the following situations:[4]
- If the patient presents with an altered mental status, metabolic acidosis, an elevated lactate:
- NAC is administered, and
- The blood acetaminophen (paracetamol) concentration is > 5,960 umol/L (900 mg/L)
- NAC cannot be administered, and
- The blood acetaminophen (paracetamol) concentration is > 4,630 umol/L (700 mg/L)
- If the blood acetaminophen (paracetamol) concentration is > 6,620 umol/L (1,000 mg/L) and NAC cannot be administered
 
Intermittent hemodialysis is preferred but hemoperfusion or continuous renal replacement therapy are acceptable alternatives if hemodialysis is not available. Exchange transfusion is an adequate alternative to hemodialysis in neonates.[4]
 
As NAC is dialyzable, NAC administration should be increased during hemodialysis. Up to 25% of NAC is removed by continuous renal replacement therapy and up to 50% with intermittent hemodialysis. The increase should match the expected losses from the extracorporeal technique.[4] It is recommended the dose is doubled while undergoing hemodialysis.[24][25]Hemodialysis should continue until clinical improvement is apparent.[4]
 

SUPPORTIVE CARE

Monitoring

The following is initially recommended, however further monitoring will be required should toxic effects become apparent.
 
Liver function tests:
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
International Normalized Ratio (INR)
Serum electrolytes:
Phosphate
Urinalysis
Renal function
Creatinine
Blood glucose
Full blood count
Arterial blood gases
Mental function
 

Hepatic

Acute Hepatic Failure

Acute hepatic failure developing from the third to sixth day following acetaminophen (paracetamol) overdose is a major concern. It is characterized by highly elevated hepatic transaminase levels (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) but with little rise in alkaline phosphatase, and modest increase in plasma bilirubin (with the exception of chronic alcoholics and those with severe hepatic damage).[26] As hepatic function deteriorates International Normalized Ratio (INR) rises, and a range of complications develop including coagulopathy, hypoglycemia, metabolic acidosis, and hepatic encephalopathy. Acetylcysteine administration should be continued regardless of time after overdose as it appears beneficial even once hepatic failure is apparent.[3]
 
Advice should be sought from a liver transplant unit if:[1]
- The International Normalized Ratio (INR) is greater than 3 at 48 hours or 4.5 at any time after overdose;
- If oliguria or creatinine is greater than 200 umol/L (2.2 mg/dL);
- If persistent acidosis develops (pH less than 7.3) or arterial lactate greater than 3 mmol/L;
- Systolic hypotension with a blood pressure less than 80 mmHg despite resuscitation;
- Hypoglycemia;
- Severe thrombocytopenia, or;
- If there is encephalopathy of any degree or any alteration of consciousness (Glasgow coma scale less than 15) not associated with co-ingestants
 
Hepatic monitoring should include:
Liver function tests including;
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
International Normalized Ratio (INR)
Blood glucose level
Blood gases including;
pH
Lactate
Mental state
 

Renal

Acute Renal Failure

Acetaminophen (paracetamol) can be nephrotoxic, even in the absence of hepatotoxicity (though this is uncommon).[27] Onset ranges from 2 to 5 days after overdose, with peak serum creatinine measured at 3 to 16 days.[26][28] The cause is acute tubular necrosis and may be more common in those with risk factors to acetaminophen (paracetamol) toxicity.[29] While the insult is typically reversible, interim support with hemodialysis may be required. Urea production will be reduced in the presence of hepatic failure and is therefore not a good index of renal function.[26] Advice should be sought from a liver transplant unit if creatinine is greater or equal to 200 umol/L (2.2 mg/dL).[30]
 
Patients should be monitored for the onset of renal failure:
Urine output
Serum creatinine
Blood urea nitrogen (urea)
Proteinuria
Hematuria
Loin pain may occur
 
Manage following standard treatment protocols for acute renal failure.
 

Hematologic

Coagulopathy

Coagulopathy is a common occurrence following acute hepatic failure. Coagulopathy should be managed in conjunction with hepatic failure. Alteration of coagulopathy is often seen before peak hepatic dysfunction.[31]
 
Patients should be monitored for increased International Normalized Ratio (INR).
 

Thrombocytopenia

Common in those with acetaminophen (paracetamol) induced acute hepatic failure and likely related to disseminated intravascular coagulation,[32] but rarely of significance in those without hepatotoxicity.[33] Monitoring for thrombocytopenia should be undertaken if acute hepatic failure develops. Platelets may be administered if the count is less than 50 x 10 to the power of 9/L.

Monitor:
White blood cell count
Platelet count
 
Manage thrombocytopenia using standard treatment protocols.
 

Hemolysis

Patients with glucose-6-phosphate dehydrogenase deficiency may be at risk of hemolysis following acetaminophen (paracetamol) overdose.[34][35][36]
 
Patients should be monitored for evidence of hemolysis:
Jaundice
Pallor
Hemoglobinuria
Anemia
Peripheral blood smear
Reticulocytosis
Heinz bodies
Cell fragments
Whole blood hemoglobin (may be decreased)
Free plasma hemoglobin (may be increased) 
Serum haptoglobin (may be decreased)
Spherocytes (may be present)
Red cell glucose-6-phosphate dehydrogenase testing may be indicated
 
Follow standard protocols for the management of hemolysis.
 

Cardiovascular

Hypotension

Hypotension may follow acetaminophen (paracetamol) ingestion[37] and is usually related to hepatotoxicity.
 
Patients should be closely monitored for onset of hypotension. Should this occur in association with hepatic failure, invasive hemodynamic monitoring is recommended as part of management.

Cardiotoxicity

In those with severe acetaminophen (paracetamol) poisoning, an electrocardiogram (ECG) during the first 48 hours may show minor non-specific S-T changes and T-wave flattening with U-waves, possibly related to hypophosphatemia. Serious cardiovascular abnormalities and hypotension, if they occur, are likely secondary to acute hepatic failure.[26]
 
Patients suffering acute hepatic failure from acetaminophen (paracetamol) toxicity should be monitored with an ECG for cardiac dysrhythmia.

Metabolic

Metabolic Acidosis

Metabolic (lactic) acidosis following acetaminophen (paracetamol) overdose is typically a consequence of hepatic failure and should be treated as such. However, it has been described following massive overdose (associated with central nervous system depression) in the absence of clinical liver failure.[38][39] In such cases acidosis is considered due to early mitochondrial inhibition following glutathione depletion and before cellular damage.[40] Patients should be monitored for onset of acidosis if presenting with either very high acetaminophen (paracetamol) concentrations or depressed level of consciousness. Hemodialysis is recommended in patients presenting with an altered mental status, metabolic acidosis, and an elevated lactate with very high blood acetaminophen (paracetamol) concentrations, especially if NAC cannot be administered.[4] If hepatic injury is present, advice should be sought from a liver transplant unit if there is persistent acidosis (pH less than 7.3) or arterial lactate greater than 3 mmol/L.[1]
 
Monitor:
Arterial blood gases (pH, bicarbonate, pCO2, pO2)
Plasma lactate
Base excess
 
Follow standard protocols for the management of metabolic acidosis.
 

Hypoglycemia

Hypoglycemia has been reported[41] and is most likely a consequence of acute hepatic failure and should be managed in conjunction with this condition. Patients with severe hepatic failure should be monitored for hypoglycemia.
 
Monitor serum glucose.
 

Hypophosphatemia

Hypophosphatemia may occur as a result of either hepatic or renal failure due to acetaminophen (paracetamol) overdose,[42] but would appear more likely due to the later.[43]

Monitor serum phosphate

Treat following standard protocols for hypophosphatemia.

Respiratory

Pulmonary Edema

Acute lung injury has been reported as common in those suffering acetaminophen (paracetamol) induced fulminant hepatic failure.[44]

Non-cardiogenic pulmonary edema may manifest with desaturation and pulmonary rales. On occasion frothy, pink sputum may be apparent. Monitoring for this condition should include:
Chest auscultation
Oxygen saturations
Arterial blood gases
Chest X-ray
 
Follow standard protocols for the management of non-cardiogenic pulmonary edema.
 

Gastrointestinal

Pancreatitis

Pancreatitis occurs rarely following acetaminophen (paracetamol) overdose, and appears related to prior alcohol intake or hemorrhage rather than direct acetaminophen (paracetamol) toxicity. Patients should be monitored for pancreatitis if dehydration is suspected, or their presentation is late.[33]

Observe for:
Vomiting
Persistent, severe, abdominal pain (may radiate to the back)
 
Monitor:
Full blood count
Blood glucose
Urea and electrolytes
Serum amylase and lipase concentrations
 
Follow standard protocols for the management of pancreatitis.
 

DISCHARGE CRITERIA

Patients suffering acetaminophen (paracetamol) overdose may be medically discharged following the initial (20 to 21 hour) acetylcysteine infusion provided:
 
- Clinically there is no nausea/vomiting, right upper quadrant tenderness, and no renal angle tenderness, and;
- Hepatic transaminase levels (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), and International Normalized Ratio (INR) remain normal or, if elevated, have peaked and are now falling.
 
In other cases continued acetylcysteine infusion (100 mg/kg per 16 hours) is required until improvement.[45] If continued infusion is required discharge may occur when liver function tests, International Normalized Ratio (INR), and creatinine are shown to be normalizing.
 
Discharge after development of hepatic or renal failure, or other consequences, should follow standard protocols for those conditions.
 

FOLLOW UP

Standard protocols should be used for follow-up of patients suffering hepatic or renal failure, including advice that patients should abstain from alcohol for six weeks to allow regeneration of the liver.
 
Patients should be referred for psychiatric assessment as appropriate.
 

PROGNOSIS

Full recovery from both hepatic and renal damage due to acetaminophen (paracetamol) toxicity is usual, but not inevitable.

SIGNS AND SYMPTOMS

Initial manifestations of acetaminophen (paracetamol) intoxication may be absent or may only include gastrointestinal effects, malaise, pallor, and diaphoresis.[46][47] Rarely, following massive overdose, there may be an initial metabolic acidosis and coma.[5][38]
 
Hepatic damage is a common feature of acetaminophen (paracetamol) toxicity and further signs and symptoms become apparent if hepatotoxicity develops. As time after overdose increases signs and symptoms associated with acute hepatic failure including right upper quadrant tenderness, hypotension, acidosis, coagulopathy, encephalopathy, and hypoglycemia may develop.[47][48][49] Jaundice is not evident as an early sign but develops as hepatic failure progresses.[47] Additionally, an initial increase in INR can be seen in the first 24 to 48 hours which appears to result from an inhibition of the activation of vitamin K dependent coagulation factors.[50] Later, coagulopathy is typically a result of liver failure.
 
Renal failure associated with acetaminophen (paracetamol) overdose may rarely appear acutely, or more usually over a period of days and in association with hepatotoxicity/failure.[33] Cardiovascular concerns are rarely an acute consequence of poisoning, but hypotension and myocardial injury may appear in patients with fulminant hepatic failure as part of multisystem organ failure.[51]
 

Onset/Duration of Symptoms

Acetaminophen (paracetamol) in the form of liquid formulations and oro-dispersable tablets are more quickly absorbed than standard tablets,[52] so may alter the onset of symptoms. Modified release tablets may additionally alter the time course of toxicity.
 
Four phases of acute acetaminophen (paracetamol) toxicity have been described.[46]
 
Phase 1 (0.5 to 24 hours after overdose): During the first 24 hours following acute overdose a patient may have few if any signs or symptoms. However, they may demonstrate malaise, anorexia, nausea, vomiting, pallor, and diaphoresis.[46][47]Rarely, following massive overdoses, metabolic acidosis and coma may occur in this phase as a direct toxic effect.[5][38]
 
Phase 2 (24 to 72 hours after overdose): Previous symptoms subside. Right upper quadrant pain may appear indicating hepatic damage with associated raised hepatic transaminases. International Normalized Ratio (INR) increases. Renal function may begin to deteriorate, however blood urea may remain low due to decreased hepatic urea formation.[46][47]
 
Phase 3 (72 to 96 hours after overdose): Continuing hepatic centrilobular necrosis with associated coagulation defects, hypoglycemia, metabolic acidosis, and jaundice. Renal failure and cardiac complications frequently occur. Hepatic encephalopathy and death may ensue.[46][47]
 
Phase 4 (4 days to 2 weeks after overdose): If phase 3 is survived complete resolution of hepatic and renal function is usual.[46][53]
 

Severity of Poisoning

Mild Acetaminophen (Paracetamol) ToxicityModerate Acetaminophen (Paracetamol) ToxicitySevere Acetaminophen (Paracetamol) Toxicity
Malaise
Nausea
Vomiting
Pallor
Diaphoresis
Upper right quadrant pain
Increased INR
Metabolic acidosis
Hypoglycemia
Jaundice
Renal failure
Fulminant hepatic failure
Hepatic encephalopathy
Coma
 

ACUTE EFFECTS (ORGAN SYSTEM)

Gastrointestinal

Anorexia[47][41][54]
Nausea[47][41]
Vomiting[47][41]
Abdominal pain[55][56][57]
Hyperamylasemia[55][58][59][60] (uncommon)
Pancreatitis[55][58][59][60] (uncommon)
 

Hepatic

Elevated liver enzymes[41][61][62][63][64][65]
Increased International Normalized Ratio (INR)[63][66][67]
Coagulopathy[48][66]
Hepatic encephalopathy[62][64][69][54]
Fulminant hepatic failure[56][63][67][70][71][54]
Centrilobular hepatic necrosis[54]
 

Renal

Proteinuria[72]
Hematuria[72]
Acute tubular necrosis[41][63][73][74][54]
 

Metabolic

Hypoglycemia[41][54]
Hypothermia[24]
Metabolic acidosis[5][38][77][78]
 

Cardiovascular

Tachycardia[54]
Hypotension[37][54]
Myocardiopathy[47]
ST elevation[79][80]
T wave inversion[79][80]
 

Neurologic

Malaise[81]
Confusion[81][82]
Altered mood[71]
Stupor[81][82]
Cerebral edema[83]
 

Dermatologic

Diaphoresis[47]
 

Hematologic

Coagulopathy[48][66]
Increased International Normalized Ratio (INR)[63][66][67][50]
 

CHRONIC EFFECTS

Symptoms in chronic situations are broadly similar to acute ones. Heptotoxicity and its complications are the major concern.[86][85]
 

TOXICITY

HUMAN

Acute

Child

Children appear less susceptible to hepatotoxicity from acetaminophen (paracetamol) than adults. Toxicity following pediatric exploratory ingestions is rare.[1][87] However, the exact toxic dose is still subject to debate. Oro-dispersible formulas may present an increased risk over standard tablets due to their near immediate disintegration when in contact with saliva.[52]
 
Medical attention is warranted for ingestions of 200 mg/kg or more in children 6 years or under, or the lesser of 10 g or 200 mg/kg in children over 6 years.[1][88]
 

Adult

Acetaminophen (paracetamol) induced hepatotoxicity may occur in adults after large doses. In a study of patients over 12 years of age, a single dose of less than 12 g can cause severe hepatotoxicity, and death has occurred with doses over 15 g.[89]
 
Medical attention is warranted following ingestions of the lesser of 10 g or 200 mg/kg acetaminophen (paracetamol).[1][88]
 
Case Studies
8 g modified release Acetaminophen (paracetamol)(ingested)
35 year female: 4 hour acetaminophen concentration was 695 umol/L, 6 hour concentration was 950 umol/L. Asymptomatic at all times
Supportive care, including acetylcysteine after 2nd acetaminophen concentration[90]
Recovered[90]
13 g (but potentially more) Acetaminophen (paracetamol)(ingested)
24 year female (alcohol abuse suspected): developed nausea, vomiting, and anorexia within hours of ingestion. Presented at hospital 2 days later with abdominal pain and discharged soon after. Nausea worsened and hematemesis occurred. On second admission was comatose and tachycardic. Later developed centrilobular hepatic necrosis, renal tubular necrosis, encephalopathy, hypotension, and hypoglycemia
Supportive care, including pressors[54]
Fatal[54]
249 mg/kg (19.95 g) modified release Acetaminophen (paracetamol)(ingested)
17 year male: Acetaminophen concentration of 1,291 umol/L at 9.5 hours. Peak ALT of 7,516 IU/L at 67 hours
Supportive care, including acetylcysteine over 101 hours[91]
Recovered[91]
290 mg/kg (17.6 g) modified release Acetaminophen (paracetamol)(ingested)
17 year female: Acetaminophen concentration of 738 umol/L at 12 hours. Peak ALT of 128 IU/L at 24 hours
Supportive care, including acetylcysteine over 53 hours[91]
Recovered[91]
318 mg/kg (23.725 g) modified release Acetaminophen (paracetamol)(ingested)
28 year male: Acetaminophen concentration of 1,177 umol/L at 12 hours. Peak ALT of 132 IU/L at 168 hours
Supportive care, including acetylcysteine over 21 hours[91]
Recovered[91]
332 mg/kg (23.9 g) modified release Acetaminophen (paracetamol)(ingested)
18 year male: Acetaminophen concentration of 502 umol/L at 4 hours. Peak ALT of 90 IU/L at 120 h
Supportive care, including acetylcysteine over 36 hours[91]
Recovered[91]
945 mg/kg (75.84 g) modified release Acetaminophen (paracetamol)(ingested)
58 year male: Acetaminophen concentration of 2,161 umol/L at 4.5 hours. Peak ALT of 1,232 IU/L at 89 hours
Supportive care, including acetylcysteine over 133 hours[91]
Recovered[91]
1,185 mg/kg (64 g) modified release Acetaminophen (paracetamol)(ingested)
25 year female: Nausea and vomiting within a couple of hours. Mild coagulopathy was noted at 48 hours. Blood acetaminophen concentration of 2,235 umol/L at 14.5 hours and 2,487 umol/L at 20 hours
Supportive care, including anti-emetics and acetylcysteine (treatment did not start until 14.5 hours post-ingestion)[92]
Recovered[92]
 

Chronic

Chronic overdose, for example ingestion of several high 'therapeutic' doses of acetaminophen (paracetamol) over 1 to 2 days, or multiple minor overdoses over a short period of time, may produce moderate or even severe hepatic damage.[86]
 
The staggered dose required to produce acetaminophen (paracetamol) toxicity has yet to be established.
 
Medical attention is warranted for children 6 years or under who ingest 200 mg/kg or more over a single 24 hour period, 150 mg/kg per 24 hours for the preceding 48 hours, or 100 mg/kg per 24 hours more than 48 hours.[1]
 
Medical attention is warranted for adults and children over 6 years who ingest the lesser of 10 g or 200 mg/kg or more over a single 24 hour period, the lesser of 6 g or 150 mg/kg per 24 hours for the preceding 48 hours, or the lesser of 4 g or 100 mg/kg per 24 hours for more than 48 hours in patients with symptoms indicating possible liver injury e.g. abdominal pain or nausea or vomiting.[1]
 

Child

Case Studies
233 mg/kg Acetaminophen (paracetamol) over a 36 to 48 hour period(ingested)
7 month male (pre-existing fever, it was unknown about the high dose of acetaminophen at the initial time of presentation at hospital): vomiting, tachycardia, drowsiness, melena, and abdominal distension. Six hours after admission developed seizures, hypoglycemia, increased liver enzymes, increased INR, and increased total bilirubin. Later developed metabolic acidosis and shock
Supportive care, including IV fluids, antibiotics, vitamin K, intubation, ventilation, and acetylcysteine[85]
Fatal. Life support was withdrawn[85]
 

Adult

Case Studies
17,000 mg acetaminophen (paracetamol) over 4 days and 1 morning(ingested)
45 year male (HIV positive, hepatitis B, Hepatitis C, IV heroin abuse, and starvation over the period of acetaminophen administration): worsening weakness, malaise, and nausea over the 4 days of acetaminophen ingestion, and hepatotoxicity
Supportive care, including acetylcysteine, IV infusions of glucose, electrolytes, amino acids, vitamin K, sucralfate, and methadone[93]
Recovered[93]
6 g acetaminophen (paracetamol) daily for 2 weeks(ingested)
22 year female (19 weeks pregnant): abdominal pain and fulminant hepatic failure
Supportive care, including acetylcysteine, bicarbonate, and liver transplant[94]
The mother required re-operation due to post-operative complications. The fetus was viable at this stage. From post-operative day 6 to 17 the fetus developed ascites, pericardial effusion, ventriculomegaly, hydrocephalus, subarachnoid fluid, compression of the cavum septum pellucidum, and lateral herniation of the brain. The fetus was electively aborted. The mother survived[94]
 

ANIMAL

Cats
 
Cats are very susceptible to toxicity as they have limited ability to metabolize acetaminophen (paracetamol) due to a limited capacity of their glucuronidation pathway and/or saturation of their sulfate conjugation pathway.[95] As little as 50 to 60 mg/kg orally may be toxic.[96]
 
Signs may occur within a few hours of ingestion and include depression, anorexia, vomiting, cyanosis, edema of the face and extremities, methemoglobinemia, dyspnea, hepatotoxicity, and death. Hematuria and hemoglobinuria usually appear first, when blood methemoglobin levels are around 20%.[96] Cats typically do not develop major hepatotoxicity although this may be due to cats dying from hypoxia secondary to methemoglobinemia at doses that are too low to produce hepatic necrosis.[96]
 
Cat
60 mg/kg acetaminophen (paracetamol)
21.7% methemoglobinemia within 4 hours; clinical effects included depression, hematuria, hemoglobinuria and increases in ALT[97]
120 mg/kg acetaminophen (paracetamol)
45.5% methemoglobinemia within 4 hours; clinical effects included salivation, vomiting, depression, mild facial edema, hematuria, and increases in ALT.[97]
 
Dogs
 
Dogs do have the ability to metabolize acetaminophen (paracetamol), however, methemoglobinemia is a concern as is hepatic damage. Toxic doses for dogs are probably greater than or equal to 150 mg/kg.[96]
 
Signs develop within one to two hours of ingestion and are progressive, consisting of anorexia, salivation, vomiting, hypovolemia, depression, methemoglobinemia, hematuria or hemoglobinuria, and edema of the face and/or paws. Muscle tremors or rarely seizures may occur, possibly through triggering of latent epilepsy. Hematuria and hemoglobinuria usually appear first, when blood methemoglobin levels are around 20%. Signs may persist 12 to 48 hours. Acute hepatic failure may follow initial signs. Death may occur 18 to 36 hours post ingestion.[96]
 
Dogs administered 3 doses of 750 mg/kg initially, 200 mg/kg 9 hours later, and 200 mg/kg at 24 hours after the initial dose by subcutaneous injection consistently developed fulminant hepatic failure. No deaths occurred within the first 36 hours.[98]
 
Dog
200 mg/kg acetaminophen (paracetamol)
18.8% methemoglobinemia[97]
500 mg/kg acetaminophen (paracetamol)
51.9% methemoglobinemia[97]
1 g/kg acetaminophen (paracetamol)
Brown mucous membranes, recumbent, hypovolemic, severe hemolytic anemia, decreased coagulation, RBC glutathione concentration that was 10% of reference values[99]
 
Paracetamol (Acetaminophen):
LD50 Oral, Mouse
338 mg/kg338 mg/kg/[100]
LD50 Oral, Rat
2,400 mg/kg2,400 mg/kg/[100]
LD50 IP, Mouse
367 mg/kg367 mg/kg/[100]
LD50 IP, Rat
1,205 mg/kg1,205 mg/kg/[100]
LD50 SC, Mouse
310 mg/kg310 mg/kg/[100]

BIOLOGICAL LEVELS - TOXIC

Acetaminophen (Paracetamol)
 

SI Unit Conversion

To convert an acetaminophen (paracetamol) concentration expressed in mg/L into umol/L:
Multiply the mg/L by 6.6155
 
To convert an acetaminophen (paracetamol) concentration expressed in umol/L into mg/L:
Multiply the umol/L by 0.1512
 
Outside of the United States most laboratories report acetaminophen (paracetamol) concentration expressed in umol/L. It is important to check what units your laboratory uses before referring to the nomogram.
 

Toxic Serum Level

A serum concentration versus time curve or Acetaminophen (Paracetamol) Nomogram has been constructed to provide an indication of potentially hepatotoxic acetaminophen (paracetamol) serum concentrations. Note this graph displays the acetaminophen (paracetamol) concentration in both umol/L and mg/L.
 

REPRODUCTION

PREGNANCY

Acetaminophen (paracetamol) is routinely used during all stages of pregnancy for pain relief and to lower elevated body temperature. In therapeutic doses, it probably is safe to use in the short term.[101]
 
Acetaminophen (paracetamol) crosses the placenta and is transformed by fetal hepatocytes into the toxic metabolite.[102] While it is felt the fetus is less susceptible to hepatic damage than adults,[102] an association is indicated between maternal first trimester overdose and abortion within 2 to 3 weeks.[103] Though transplacental transport of acetylcysteine is not thought to be clinically significant,[11] delay in initiation of acetylcysteine treatment is associated with increased incidence of spontaneous abortion and fetal death.[12] Neither acetaminophen (paracetamol) nor acetylcysteine appears teratogenic and termination of pregnancy is not indicated in most circumstances after acetaminophen (paracetamol) overdose.[13]
 
A 19 week pregnant female who was ingesting 6 g acetaminophen daily for 2 weeks developed hepatic encephalopathy and fulminant hepatic failure. As the fetus was initially deemed viable, maternal liver transplant took place. Due to maternal complications a further surgery was required. Six days post-operation the fetus developed complications of fetal ascites and pericardal effusion, and later developed ventriculomegaly, hydrocephalus, subarachnoid fluid, compression of the cavum septum pellucidum, and lateral herniation of the brain. The brain injury was deemed to be non-conducive with life and the fetus was aborted.[94]
 
FDA Classification (before July 2015):
B
 
Australian Classification:
A
 
For full details of the Australian ADC pregnancy classification, as well as the FDA classification (used prior to July 2015), Click here.
 

LACTATION

Acetaminophen (paracetamol) is excreted into breast milk in low concentrations.[104][105][106][107]
 
The American Academy of Pediatrics considers acetaminophen (paracetamol) to be compatible with breast-feeding.[108]
 

TOXIC MECHANISM

At therapeutic doses, 90% of acetaminophen (paracetamol) is converted to non-toxic glucuronide and sulfate conjugates, and 5% is excreted in the urine unchanged. The other 5% is oxidized in the liver by P450 2E1, P450 1A2 and P450 3A4 to N-acetyl-p-benzoquinoneimine (NAPQI).[109] At therapeutic amounts glutathione binds with NAPQI to form a non-toxic conjugate. In overdose, glucuronide and sulfate conjugation becomes saturated and an increased proportion of NAPQI is formed. Glutathione levels are depleted, as the demand for glutathione is higher than the formation of glutathione.[110] This means that NAPQI remains in its toxic form in the liver and can bind to cysteine containing macromolecules.[111] This can cause hepatocellular damage, in particular centrilobular necrosis.[46] The exact mechanism of damage in the liver is unknown. NAPQI can also be produced in the kidney leading to renal damage.[112]
 
Both acetaminophen (paracetamol) and NAPQI are capable of inhibiting hepatic mitochondrial respiration,[113] generally following massive ingestions.[38][24]
 

THERAPEUTIC DRUG INFORMATION

INDICATIONS

This is intended as a guide only. For a more comprehensive list, refer to manufacturer's information.
 
Generally, indicated for:[114][115][116]
Mild to moderate analgesia
Pyrexia
 

THERAPEUTIC DOSE RANGE

This is intended as a guide only. For a more comprehensive list, refer to manufacturer's information.
 

Child

Analgesia & Pyrexia[115][117][118][119][120]
Oral
Under 3 months
200 mg acetaminophen (paracetamol) daily (in divided doses)
Maximum dose is 60 mg/kg daily
4 to 11 months
240 to 480 mg acetaminophen (paracetamol) daily (in divided doses)
Maximum dose is 60 mg/kg daily
12 to 23 months
600 mg acetaminophen (paracetamol) daily (in divided doses)
Maximum dose is 60 mg/kg daily
2 to 3 years
800 mg acetaminophen (paracetamol) daily (in divided doses)
Maximum dose is 60 mg/kg daily
4 to 5 years
1,200 mg acetaminophen (paracetamol) daily (in divided doses)
Maximum dose is 60 mg/kg daily
6 to 8 years
1.600 mg acetaminophen (paracetamol) daily (in divided doses)
Maximum dose is 60 mg/kg daily
9 to 10 years
2,000 mg acetaminophen (paracetamol) daily (in divided doses)
Maximum dose is 60 mg/kg daily
11 years
2,400 mg acetaminophen (paracetamol) daily (in divided doses)
Maximum dose is 60 mg/kg daily
Over 12 years
Usual dose is 4  g acetaminophen (paracetamol) daily (in divided doses)
Maximum 4 g daily
 
Rectal
Under 6 months
Generally not recommended but may be prescribed by a doctor at individualized doses
6 months to 3 years
500 to 800 mg acetaminophen (paracetamol) daily (in divided doses)
4 to 5 years
1,200 mg acetaminophen (paracetamol) daily (in divided doses)
6 to 8 years
1.600 mg acetaminophen (paracetamol) daily (in divided doses)
9 to 10 years
1,600 to 2,000 mg acetaminophen (paracetamol) daily (in divided doses)
11 years
1,600 to 2,400 mg acetaminophen (paracetamol) daily (in divided doses)
Over 12 years
325 to 650 mg acetaminophen (paracetamol) daily (in divided doses)
 
Injection
<10 kg
7.5 mg/kg acetaminophen (paracetamol) up to 4 times daily
10 to 50 kg
15 mg/kg acetaminophen (paracetamol) up to 4 times daily
> 50 kg
1 g acetaminophen (paracetamol) up to 4 times daily
 

Adult

Analgesia or Pyrexia[114][115][117][118][119]
Oral
3.9 to 4 g acetaminophen (paracetamol) daily (in divided doses)
Maximum 4 g daily
Rectal
1.95 to 3.9 g acetaminophen (paracetamol) daily (in divided doses)
Maximum of 4 g daily
Injection
<50 kg
15 mg/kg acetaminophen (paracetamol) up to 4 times daily
>50 kg
1 g acetaminophen (paracetamol) up to 4 times daily
 

PHARMACOLOGICAL ACTION

The pharmacological action of acetaminophen (paracetamol) is not fully understood. It has been hypothesized that the mechanisms involved for producing analgesia and antipyrexia are similar to that of the salicylates but with only weak anti-inflammatory effects.
 
It is known that acetaminophen (paracetamol) selectively inhibits prostaglandin synthesis, predominantly in the central nervous system and to a lesser extent in the periphery.[121] Acetaminophen (paracetamol) also lowers body temperature by acting on the hypothalamus to increase vasodilatation and peripheral blood flow to aid heat dissipation. This occurs largely in patients with a fever, with little change in body temperature in subjects with normal body temperature. Acetaminophen (paracetamol) is also a weak inhibitor of the enzyme cyclo-oxygenase, but only in the presence of a high concentration of peroxides.[122]
 

KINETICS

ABSORPTION

Oral Absorption
Rapidly absorbed from the gastrointestinal tract[123][124]
Oro-dispersible tablets start disintegrating within seconds of contact with saliva[52]
Rectal Absorption
Slower than oral route[125][126]
Effect of Food
High carbohydrate meals appear to delay absorption[127]
Food does not affect the total amount absorbed[127]
Other Factors Affecting Absorption
Absorption was slow and incomplete in vegetarians compared with non-vegetarians[128]
Bioavailability
68 to 90%[123]
Oro-dispersible tablets absorption is 32% greater than standard tablets over the first hour[129]
Onset of Action
Within 30 minutes[46]
Duration of Action
~4 hours[46]
Time to Peak Plasma Levels
Immediate release: 10 minutes to 1.4 hours[123][130][131][132]
Extended release: 60 to 180 min[133][130][134]
 
In overdose time to peak plasma levels is delayed[123]
 

DISTRIBUTION

Distribution
  1. Rapidly and uniformly distributed to most of the body tissues[124][134]
Volume of Distribution
  1. 0.9 to 1.0 L/kg[46][135][136]
Plasma Protein Binding
  1. 5 to 20% at therapeutic doses[46]
  2. 15 to 50% during acute intoxication[137][138]
Lipid Solubility
Crosses the placenta[102]
Is excreted in breast milk[104][105][106][107]
 

METABOLISM

Metabolism
  1. Predominantly by the liver, 98%[139]
Metabolites
Inactive:
  1. Glucuronide metabolites[139]
  2. Sulfate metabolites[139]
  3. N-acetyl-p-benzoquinoneimine (NAPQI), minor hydroxylated metabolite[109][140]
Major Metabolic Pathways
Parent:
  1. Adults - Acetaminophen (paracetamol) conjugation to glucuronide (42%) and sulfate (52%) metabolites.[139] The remainder is oxidized in the liver by P450 2E1, P450 1A2, and P450 3A4 to NAPQI.[109]
  2. After 12 years of age - Glucuronide conjugation predominates.[139] 
  3. Infants - Sulfate conjugation predominates with a gradual shift towards glucuronide conjugation in older children.[139]
N-acetyl-p-benzoquinoneimine (NAPQI):
  1. Rapidly conjugated with glutathione at therapeutic doses[46][141]
  2. In overdose the glucuronidation pathway becomes saturated allowing NAPQI to cause cell toxicity[46][141]
Saturation of Enzymes
  1. In overdose the glucuronidation and sulfation pathways become saturated[141][142]
Other Factors Affecting Metabolism
  1. Metabolism is impaired in severe poisoning with liver damage; prolongation of plasma half-life occurs[143]
 

ELIMINATION

Excretion
Urine
  1. Mainly as glucuronide and sulfate conjugates[126]
  2. Less than 5% excreted unchanged[124][126][135]
Half-life
Therapeutic
  1. Standard release: 1 to 3 hours[133][46][123][130][135][144]
  2. Modified release: half-life is similar[133][130]
Overdose
  1. Half-life may be prolonged in severe poisoning with liver damage[63][143][145]
  2. Half-life following modified release overdose appears extremely variable, 3.3 to 11 hours[92][146][147]
Active Metabolites
Glucuronide metabolite
  1. 3.5 to 3.9 hours[130]
Sulfate metabolite
  1. 3.8 to 3.9 hours[130]
Clearance Rate
  1. 3.9 to 5.7 mL/kg/min[136][144][148]
Time to Completion
  1. 85 to 95% excreted within 24 hours[126]
Potential for Accumulation
  1. N-Acetyl-p-benzoquinoneimine may accumulate following overdose and cause tissue damage[109][142]
 

IDENTIFICATION

PRODUCT INFORMATION

Tablets and capsules range from 80 to 665 mg acetaminophen (paracetamol), commonly 500 mg. Sustained release formulations are available in 665 mg strength tablets and capsules. Oro-dispersible forms are available.

Formulations for injection contain 10 mg/mL acetaminophen (paracetamol).

Oral solutions range from 24 to 100 mg/mL acetaminophen (paracetamol).

Hot drink powders range from 500 to 1,000 mg/sachet, commonly 1,000 mg/sachet acetaminophen (paracetamol).

The packaging of each trade product will include information on the exact quantity of acetaminophen (paracetamol) and whether the formulation is sustained release.

OTHER NAME(S)

Common Names

4-HydroxyacetanilideAcetaminofenoAcetaminophen
APAPAsetaminofenN-Acetyl-p-aminophenol
N-acetyl-para-aminophenolP acetamidophenolParacetamol
ParacetamolisParacetamolumParasetamol
Parasetamoli
 
 
 

Chemical Name

Acetaminophen (Paracetamol):
N-(4-Hydroxyphenyl)acetamide 4'-Hydroxyacetanilide N-Acetyl-p-aminophenol
 

“Street” Names

CandiesCapricorn
DuckGreen Capricorn
Green clubsKO
Orange candiesPink KO
Pokemon
 
 
These street names refer to products which are contaminated with acetaminophen (paracetamol).
 

CODES

ATC CLASSIFICATION

Other Analgesics And Antipyretics - AnilidesOther Analgesics And Antipyretics
N02B E01
Paracetamol
N02B E51
Paracetamol, Combinations excl. Psycholeptics
N02B E71
Paracetamol, Combinations with Psycholeptics
N02B E
 

CAS NUMBER

Acetaminophen (Paracetamol):
103-90-2
 

MOLECULAR FORMULA

Acetaminophen (Paracetamol):
C8H9NO2
 

PHYSICOCHEMICAL PROPERTIES

Large, monoclinic prisms
 
Specific Gravity (water = 1)
1.293 1.293% degrees C[149]
Molecular Weight
151.16 151.16% degrees C[149]
Melting Point
169 to 170.5 169 to 170.5% degrees C[149]
Solubility
Cold water: very slightly soluble[149]
Hot water: moderately soluble[149]
Methanol: soluble[149]
Ethanol: soluble[149]
Acetone: soluble[149]
Ethyl acetate: soluble[149]
Ether: slightly soluble[149]
 

REFERENCES

 
[1] Chiew AL, Fountain JS, Graudins A, Isbister GK, Reith D, Buckley NA. Summary statement: new guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust 2015 Sep 7; 203 (5): 215-8.
[2] Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999; 37 (6): 753-7.
[3] Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, Williams R. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991 Oct 26; 303 (6809): 1026-9.
[4] Gosselin S, Juurlink DN, Kielstein JT, Ghannoum M, Lavergne V, Nolin TD, Hoffman RS. Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2014 Sep-Oct; 52 (8): 856-67.
[5] Zezulka A, Wright N. Severe metabolic acidosis early in paracetamol poisoning. Br Med J (Clin Res Ed) 1982 Sep 25; 285 (6345): 851-2.
[6] Fountain JS, Beasley DM. Activated charcoal supercedes ipecac as gastric decontaminant. N Z Med J 1998 Oct 23; 111 (1076): 402-4.
[7] Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning? J Toxicol Clin Toxicol 1999; 37 (6): 759-67.
[8] Prescott LF, Illingworth RN, Critchley JA, Proudfoot AT. Intravenous N-acetylcysteine: still the treatment of choice for paracetamol poisoning. [Letter] Br Med J 1980 Jan 5; 280 (6206): 46-7.
[9] Cumberland-Pharmaceuticals. Acetadote (Acetylcsyteine) Injection - Package Insert. Nashville TN: Cumberland Pharmaceuticals Inc, 2011: [Cited 27 Jan 2012]. URL: http://www.acetadote.net
[10] ACMT Position Statement: Duration of Intravenous Acetylcysteine Therapy Following Acetaminophen Overdose. J Med Toxicol 2017 Mar; 13 (1): 126-127.
[11] Selden BS, Curry SC, Clark RF, Johnson BC, Meinhart R, Pizziconi VB. Transplacental transport of N-acetylcysteine in an ovine model. Ann Emerg Med 1991 Oct; 20 (10): 1069-72.
[12] Riggs BS, Bronstein AC, Kulig K, Archer PG, Rumack BH. Acute acetaminophen overdose during pregnancy. Obstet Gynecol 1989 Aug; 74 (2): 247-53.
[13] Janes J, Routledge PA. Recent developments in the management of paracetamol (acetaminophen) poisoning. Drug Saf 1992 May-Jun; 7 (3): 170-7.
[14] Mant TG, Tempowski JH, Volans GN, Talbot JC. Adverse reactions to acetylcysteine and effects of overdose. Br Med J (Clin Res Ed) 1984 Jul 28; 289 (6439): 217-9.
[15] Bailey B, McGuigan MA. Management of anaphylactoid reactions to intravenous N-acetylcysteine. Ann Emerg Med 1998 Jun; 31 (6): 710-5.
[16] Schmidt LE, Dalhoff K. Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning. Br J Clin Pharmacol 2001 Jan; 51 (1): 87-91.
[17] Sung L, Simons JA, Dayneka NL. Dilution of intravenous N-acetylcysteine as a cause of hyponatremia. Pediatrics 1997 Sep; 100 (3 Pt 1): 389-91.
[18] Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009 Dec; 47 (10): 911-1084.
[19] Schmidt LE, Knudsen TT, Dalhoff K, Bendtsen F. Effect of acetylcysteine on prothrombin index in paracetamol poisoning without hepatocellular injury. Lancet 2002 Oct 12; 360 (9340): 1151-2.
[20] Beuhler MC, Dulaney AR. Further case details regarding IV N-Acetylcysteine overdoses. Clin Toxicol (Phila) 2011 Nov; 49 (9): 878.
[21] Oie S, Lowenthal DT, Briggs WA, Levy G. Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients. Clin Pharmacol Ther 1975 Dec; 18 (06): 680-6.
[22] Marbury TC, Wang LH, Lee CS. Hemodialysis of acetaminophen in uremic patients. Int J Artif Organs 1980 Sep; 3 (5): 263-6.
[23] Ghannoum M, Kazim S, Grunbaum AM, Villeneuve E, Gosselin S. Massive acetaminophen overdose: effect of hemodialysis on acetaminophen and acetylcysteine kinetics. Clin Toxicol (Phila) 2016 Jul; 54 (6): 519-22.
[24] Sivilotti ML, Juurlink DN, Garland JS, Lenga I, Poley R, Hanly LN, Thompson M. Antidote removal during haemodialysis for massive acetaminophen overdose. Clin Toxicol (Phila) 2013 Nov; 51 (9): 855-63.
[25] Hernandez SH, Howland M, Schiano TD, Hoffman RS. The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. Clin Toxicol (Phila) 2015 Dec; 53 (10): 941-949.
[26] Prescott LF. Paracetamol overdosage. Pharmacological considerations and clinical management. Drugs 1983 Mar; 25 (3): 290-314.
[27] Boutis K, Shannon M. Nephrotoxicity after acute severe acetaminophen poisoning in adolescents. J Toxicol Clin Toxicol 2001; 39 (5): 441-5.
[28] Eguia L, Materson BJ. Acetaminophen-related acute renal failure without fulminant liver failure. Pharmacotherapy 1997 Mar-Apr; 17 (2): 363-70.
[29] Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol 1995 Jul; 6 (1): 48-53.
[30] Murray L, Little M, Pascu O, Hoggett K. Toxicology handbook. 3rd ed. Sydney, Australia: Elsevier; 2015. p. 327-36.
[31] Gazzard BG, Henderson JM, Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 1975 Aug; 16 (8): 617-20.
[32] Hillenbrand P, Parbhoo SP, Jedrychowski A, Sherlock S. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut 1974 Feb; 15 (2): 83-8.
[33] Jones AL, Prescott LF. Unusual complications of paracetamol poisoning. QJM 1997 Mar; 90 (3): 161-8.
[34] Wright RO, Perry HE, Woolf AD, Shannon MW. Hemolysis after acetaminophen overdose in a patient with glucose-6-phosphate dehydrogenase deficiency. J Toxicol Clin Toxicol 1996; 34 (6): 731-4.
[35] Cayanis E, Gomperts ED, Balinsky D, Disler P, Myers A. G6PD hillbrow: a new variant of glucose-6-phosphate dehydrogenase associated with drug-induced haemolytic anaemia. Br J Haematol 1975 Jul; 30 (3): 343-50.
[36] Rickner SS, Cao D, Simpson SE. Hemolytic crisis following acetaminophen overdose in a patient with G6PD deficiency. Clin Toxicol (Phila) 2017 Jan; 55 (1): 74-75.
[37] Yang CC, Deng JF, Lin TJ. Pancytopenia, hyperglycemia, shock, coma, rhabdomyolysis, and pancreatitis associated with acetaminophen poisoning. Vet Hum Toxicol 2001 Dec; 43 (6): 344-8.
[38] Roth B, Woo O, Blanc P. Early metabolic acidosis and coma after acetaminophen ingestion. Ann Emerg Med 1999 Apr; 33 (4): 452-6.
[39] Steelman R, Goodman A, Biswas S, Zimmerman A. Metabolic acidosis and coma in a child with acetaminophen toxicity. Clin Pediatr (Phila) 2004 Mar; 43 (2): 201-3.
[40] Shah AD, Wood DM, Dargan PI. Understanding lactic acidosis in paracetamol (acetaminophen) poisoning. Br J Clin Pharmacol 2011 Jan; 71 (1): 20-8.
[41] Proudfoot AT, Wright N. Acute paracetamol poisoning. Br Med J 1970 Sep 5; 3 (5722): 557-8.
[42] Dawson DJ, Babbs C, Warnes TW, Neary RH. Hypophosphataemia in acute liver failure. Br Med J (Clin Res Ed) 1987 Nov 21; 295 (6609): 1312-3.
[43] Jones AF, Harvey JM, Vale JA. Hypophosphataemia and phosphaturia in paracetamol poisoning. Lancet 1989 Sep 9; 2 (8663): 608-9.
[44] Baudouin SV, Howdle P, O'Grady JG, Webster NR. Acute lung injury in fulminant hepatic failure following paracetamol poisoning. Thorax 1995 Apr; 50 (4): 399-402.
[45] Murray L, Little M, Pascu O, Hoggett K. Toxicology handbook. 3rd ed. Sydney, Australia: Elsevier; 2015. p. 435-8.
[46] Linden CH, Rumack BH. Acetaminophen overdose. Emerg Med Clin North Am 1984 Feb; 2 (1): 103-19.
[47] Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975 Jun; 55 (6): 871-6.
[48] Dargan PI, Jones AL. Acetaminophen poisoning: an update for the intensivist. Crit Care 2002 Apr; 6 (2): 108-10.
[49] Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010 Jul 17; 376 (9736): 190-201.
[50] Whyte IM, Buckley NA, Reith DM, Goodhew I, Seldon M, Dawson AH. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. Ther Drug Monit 2000 Dec; 22 (6): 742-8.
[51] Lip GY, Vale JA. Does acetaminophen damage the heart? J Toxicol Clin Toxicol 1996; 34 (2): 145-7.
[52] Ceschi A, Hofer KE, Rauber-Lüthy C, Kupferschmidt H. Paracetamol orodispersible tablets: a risk for severe poisoning in children? Eur J Clin Pharmacol 2011 Jan; 67 (1): 97-9.
[53] Hamlyn AN, Douglas AP, James OF, Lesna M, Watson AJ. Liver function and structure in survivors of acetaminophen poisoning. A follow-up study of serum bile acids and liver histology. Am J Dig Dis 1977 Jul; 22 (7): 605-10.
[54] McJunkin B, Barwick KW, Little WC, Winfield JB. Fatal massive hepatic necrosis following acetaminophen overdose. JAMA 1976 Oct 18; 236 (16): 1874-5.
[55] Gilmore IT, Tourvas E. Paracetamol-induced acute pancreatitis. Br Med J 1977 Mar 19; 1 (6063): 753-4.
[56] Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J 1966 Aug 27; 2 (5512): 497-9.
[57] Thomson JS, Prescott LF. Liver damage and impaired glucose tolerance after paracetamol overdosage. Br Med J 1966 Aug 27; 2 (5512): 506-7.
[58] Caldarola V, Hassett JM, Hall AH, Bronstein AB, Kulig KW, Rumack BH. Hemorrhagic pancreatitis associated with acetaminophen overdose. Am J Gastroenterol 1986 Jul; 81 (7): 579-82.
[59] Mofenson HC, Caraccio TR, Nawaz H, Steckler G. Acetaminophen induced pancreatitis. J Toxicol Clin Toxicol 1991; 29 (2): 223-30.
[60] Coward RA. Paracetamol-induced acute pancreatitis. [Letter] Br Med J 1977 Apr 23; 1 (6068): 1086.
[61] Singer AJ, Carracio TR, Mofenson HC. The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. Ann Emerg Med 1995 Jul; 26 (1): 49-53.
[62] Wang GS, Monte A, Bagdure D, Heard K. Hepatic failure despite early acetylcysteine following large acetaminophen-diphenhydramine overdose. Pediatrics 2011 Apr; 127 (4): e1077-80.
[63] Prescott LF, Roscoe P, Wright N, Brown SS. Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet 1971 Mar 13; 1 (7698): 519-22.
[64] Mahadevan SB, McKiernan PJ, Davies P, Kelly DA. Paracetamol induced hepatotoxicity. Arch Dis Child 2006 Jul; 91 (7): 598-603.
[65] Rumack BH, Peterson RC, Koch GG, Amara IA. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 1981 Feb 23; 141 (3 Spec No): 380-5.
[66] Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiødt FV, Ostapowicz G, Shakil AO, Lee WM. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005 Dec; 42 (6): 1364-72.
[67] Miles FK, Kamath R, Dorney SF, Gaskin KJ, O'Loughlin EV. Accidental paracetamol overdosing and fulminant hepatic failure in children. Med J Aust 1999 Nov 1; 171 (9): 472-5.
[68] Goulding R. Acetaminophen poisoning. Pediatrics 1973 Dec; 52 (6): 883-5.
[69] Schiødt FV, Bondesen S, Tygstrup N, Christensen E. Prediction of hepatic encephalopathy in paracetamol overdose: a prospective and validated study. Scand J Gastroenterol 1999 Jul; 34 (7): 723-8.
[70] Schiødt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997 Oct 16; 337 (16): 1112-7.
[71] Luria JW, Ruddy R, Stephan M. Acute hepatic failure related to chronic acetaminophen intoxication. Pediatr Emerg Care 1996 Aug; 12 (4): 291-3.
[72] Prescott LF, Proudfoot AT, Cregeen RJ. Paracetamol-induced acute renal failure in the absence of fulminant liver damage. [Letter] Br Med J (Clin Res Ed) 1982 Feb 6; 284 (6313): 421-2.
[73] Alkhuja S, Aboudan M, Menkel R. Acetaminophen toxicity induced non-oliguric acute tubular necrosis. [Letter] Nephrol Dial Transplant 2001 Jan; 16 (1): 190.
[74] Jeffery WH, Lafferty WE. Acute renal failure after acetaminophen overdose: report of two cases. Am J Hosp Pharm 1981 Sep; 38 (9): 1355-8.
[75] Cobden I, Record CO, Ward MK, Kerr DN. Paracetamol-induced acute renal failure in the absence of fulminant liver damage. Br Med J (Clin Res Ed) 1982 Jan 2; 284 (6308): 21-2.
[76] Curry RW Jr, Robinson JD, Sughrue MJ. Acute renal failure after acetaminophen ingestion. JAMA 1982 Feb 19; 247 (7): 1012-4.
[77] Flanagan RJ, Mant TG. Coma and metabolic acidosis early in severe acute paracetamol poisoning. Hum Toxicol 1986 May; 5 (3): 179-82.
[78] Wiegand TJ, Margaretten M, Olson KR. Massive acetaminophen ingestion with early metabolic acidosis and coma: treatment with IV NAC and continuous venovenous hemodiafiltration. Clin Toxicol (Phila) 2010 Feb; 48 (2): 156-9.
[79] Contractor H, Gauge V, Nabi S, Titu H, Arya S, Naqvi N. ST segment elevation secondary to paracetamol overdose. [Letter] Ther Adv Cardiovasc Dis 2011 Feb; 5 (1): 83-5.
[80] Armour A, Slater SD. Paracetamol cardiotoxicity. Postgrad Med J 1993 Jan; 69 (807): 52-4.
[81] Savides MC, Oehme FW. Acetaminophen and its toxicity. J Appl Toxicol 1983 Apr; 3 (2): 96-111.
[82] Jones Al. Recent advances in the management of late paracetamol poisoning. Emerg Med (Fremantle) 2000; 12 (1): 14–21.
[83] McCormick PA, Treanor D, McCormack G, Farrell M. Early death from paracetamol (acetaminophen) induced fulminant hepatic failure without cerebral oedema. J Hepatol 2003 Oct; 39 (4): 547-51.
[84] Meredith TJ, Goulding R. Paracetamol. Postgrad Med J 1980 Jul; 56 (657): 459-73.
[85] Ebenezer K, Agarwal I, Fleming D. Acute hepatic failure in an infant caused by acetaminophen (paracetamol) toxicity. Ann Trop Paediatr 2008 Dec; 28 (4): 301-3.
[86] Barker JD Jr, de Carle DJ, Anuras S. Chronic excessive acetaminophen use and liver damage. Ann Intern Med 1977 Sep; 87 (3): 299-301.
[87] Gee P, Ardagh M. Paediatric exploratory ingestions of paracetamol. N Z Med J 1998 May 22; 111 (1066): 186-8.
[88] Dart RC, Erdman AR, Olson KR, Christianson G, Manoguerra AS, Chyka PA, Caravati EM, Wax PM, Keyes DC, Woolf AD, Scharman EJ, Booze LL, Troutman WG. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2006; 44 (1): 1-18.
[89] Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002 Apr; 35 (4): 876-82.
[90] Graudins A, Chiew A, Chan B. Overdose with modified-release paracetamol results in delayed and prolonged absorption of paracetamol. Intern Med J 2010 Jan; 40 (1): 72-6.
[91] Graudins A. Overdose with modified-release paracetamol (Panadol Osteo®) presenting to a metropolitan emergency medicine network: a case series. Emerg Med Australas 2014 Aug; 26 (4): 398-402.
[92] Roberts DM, Buckley NA. Prolonged absorption and delayed peak paracetamol concentration following poisoning with extended-release formulation. Med J Aust 2008 Mar 3; 188 (5): 310-1.
[93] Moling O, Cairon E, Rimenti G, Rizza F, Pristerá R, Mian P. Severe hepatotoxicity after therapeutic doses of acetaminophen. Clin Ther 2006 May; 28 (5): 755-60.
[94] Franko KR, Mekeel KL, Woelkers D, Khanna A, Hemming AW. Accidental acetaminophen overdose results in liver transplant during second trimester of pregnancy: a case report. Transplant Proc 2013 Jun; 45 (5): 2063-5.
[95] Bates N, Rawson-Harris P, Edwards N. Common questions in veterinary toxicology. J Small Anim Pract 2015 May; 56 (5): 298-306.
[96] Hjelle JJ, Grauer GF. Acetaminophen-induced toxicosis in dogs and cats. J Am Vet Med Assoc 1986 Apr 1; 188 (7): 742-6.
[97] Savides MC, Oehme FW, Nash SL, Leipold HW. The toxicity and biotransformation of single doses of acetaminophen in dogs and cats. Toxicol Appl Pharmacol 1984 Jun 15; 74 (1): 26-34.
[98] Francavilla A, Makowka L, Polimeno L, Barone M, Demetris J, Prelich J, Van Thiel DH, Starzl TE. A dog model for acetaminophen-induced fulminant hepatic failure. Gastroenterology 1989 Feb; 96 (2 Pt 1): 470-8.
[99] Wallace KP, Center SA, Hickford FH, Warner KL, Smith S. S-adenosyl-L-methionine (SAMe) for the treatment of acetaminophen toxicity in a dog. J Am Anim Hosp Assoc 2002 May-Jun; 38 (3): 246-54.
[100] Lewis RJ, editor. Sax’s dangerous properties of industrial materials. 9th ed. New York: Van Nostrand Reinhold; 1996. p. 1848.
[101] Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2002. p. 6-12.
[102] Roberts I, Robinson MJ, Mughal MZ, Ratcliffe JG, Prescott LF. Paracetamol metabolites in the neonate following maternal overdose. Br J Clin Pharmacol 1984 Aug; 18 (2): 201-6.
[103] McElhatton PR, Sullivan FM, Volans GN, Fitzpatrick R. Paracetamol poisoning in pregnancy: an analysis of the outcomes of cases referred to the Teratology Information Service of the National Poisons Information Service. Hum Exp Toxicol 1990 May; 9 (3): 147-53.
[104] Berlin CM Jr, Yaffe SJ, Ragni M. Disposition of acetaminophen in milk, saliva, and plasma of lactating women. Pediatr Pharmacol (New York) 1980; 1 (2): 135-41.
[105] Bitzén PO, Gustafsson B, Jostell KG, Melander A, Wåhlin-Boll E. Excretion of paracetamol in human breast milk. Eur J Clin Pharmacol 1981; 20 (2): 123-5.
[106] Notarianni LJ, Oldham HG, Bennett PN. Passage of paracetamol into breast milk and its subsequent metabolism by the neonate. Br J Clin Pharmacol 1987 Jul; 24 (1): 63-7.
[107] Matheson I, Lunde PK, Notarianni L. Infant rash caused by paracetamol in breast milk? [Letter] Pediatrics 1985 Oct; 76 (4): 651-2.
[108] Transfer of drugs and other chemicals into human milk. Pediatrics 2001 Sep; 108 (3): 776-89.
[109] Corcoran GB, Mitchell JR, Vaishnav YN, Horning EC. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol 1980 Nov; 18 (3): 536-42.
[110] Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973 Oct; 187 (1): 211-7.
[111] Dai Y, Cederbaum AI. Cytotoxicity of acetaminophen in human cytochrome P4502E1-transfected HepG2 cells. J Pharmacol Exp Ther 1995 Jun; 273 (3): 1497-505.
[112] McMurtry RJ, Snodgrass WR, Mitchell JR. Renal necrosis, glutathione depletion, and covalent binding after acetaminophen. Toxicol Appl Pharmacol 1978 Oct; 46 (1): 87-100.
[113] Esterline RL, Ray SD, Ji S. Reversible and irreversible inhibition of hepatic mitochondrial respiration by acetaminophen and its toxic metabolite, N-acetyl-p-benzoquinoneimine (NAPQI). Biochem Pharmacol 1989 Jul 15; 38 (14): 2387-90.
[114] Panadol Osteo Medicines Data Sheet, New Zealand: GlaxoSmithKlineConsumer Healthcare; May 2012; [cited 13 February 2015]. URL: http://www.medsafe.govt.nz.
[115] Panadol Medicines Data Sheet, New Zealand: GlaxoSmithKline Consumer Healthcare; July 2012; [cited 13 February 2015]. URL: http://www.medsafe.govt.nz.
[116] McEvoy GK, editor. AHFS drug information. Bethesda (MD): American Society of Health System Pharmacists; 2014. p. 2247.
[117] Perfalgan Medicines Data Sheet, New Zealand: Bristol Myers Squibb; May 2014 (cited 12 February 2015). URL: http://www.medsafe.govt.nz.
[118] Paracetamol-AFT Medicines Data Sheet, New Zealand: AFT Pharmaceuticals; January 2013; [cited February 2014]. URL: http://www.medsafe.govt.nz.
[119] McEvoy GK, editor. AHFS drug information. Bethesda (MD): American Society of Health System Pharmacists; 2014. p. 2172.
[120] Childrens Panadol Colourfree Suspension Medicines Data Sheet, New Zealand: GlaxoSmithKline; July 2012; [cited February 15 2015]. URL: http://www.medsafe.govt.nz.
[121] Clissold SP. Paracetamol and phenacetin. Drugs 1986; 32 Suppl 4 (): 46-59.
[122] Hanel AM, Lands WE. Modification of anti-inflammatory drug effectiveness by ambient lipid peroxides. Biochem Pharmacol 1982 Oct 15; 31 (20): 3307-11.
[123] Rawlins MD, Henderson DB, Hijab AR. Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol 1977 Apr 20; 11 (4): 283-6.
[124] BRODIE BB, AXELROD J. The fate of acetophenetidin in man and methods for the estimation of acetophenetidin and its metabolites in biological material. J Pharmacol Exp Ther 1949 Sep; 97 (1): 58-67.
[125] Childrens Panadol Couourfree Suspension & Panadol Suppositories Medicines Data Sheet, New Zealand: GlaxoSmithKline; July 2012; [cited 19 March 2015]. URL: http://www.medsafe.govt.nz.
[126] Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet 1982 Mar-Apr; 7 (2): 93-107.
[127] Jaffe JM, Colaizzi JL, Barry H 3rd. Effects of dietary components on GI absorption of acetaminophen tablets in man. J Pharm Sci 1971 Nov; 60 (11): 1646-50.
[128] Prescott LF, Yoovathaworn K, Makarananda K, Saivises R, Sriwatanakul K. Impaired absorption of paracetamol in vegetarians. Br J Clin Pharmacol 1993 Sep; 36 (3): 237-40.
[129] Panadol With Optizorb Medicines Data Sheet, New Zealand: GlaxoSmithKline; January 2012; [cited 19 March 2015]. URL: http://www.medsafe.govt.nz.
[130] Chiew A, Day P, Salonikas C, Naidoo D, Graudins A, Thomas R. The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. Emerg Med Australas 2010 Dec; 22 (6): 548-55.
[131] Junior Parapaed Medicines Data Sheet, New Zealand: AFT Pharmaceuticals; August 2003; [cited 19 March 2015]. URL: http://www.medsafe.govt.nz.
[132] Heading RC, Nimmo J, Prescott LF, Tothill P. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 1973 Feb; 47 (2): 415-21.
[133] Tan C, Graudins A. Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. Emerg Med Australas 2006 Aug; 18 (4): 398-403.
[134] McEvoy GK, editor. AHFS Drug Information. Bethesda (MD): American Society of Health-System Pharmacists; 1995. p. 1410-7.
[135] Perucca E, Richens A. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. Br J Clin Pharmacol 1979 Feb; 7 (2): 201-6.
[136] Clements JA, Prescott LF. Data point weighting in pharmacokinetic analysis: intravenous paracetamol in man. J Pharm Pharmacol 1976 Sep; 28 (9): 707-9.
[137] Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press; 1990. p. 658.
[138] Gazzard BG, Ford-Hutchinson AW, Smith MJ, Williams R. The binding of paracetamol to plasma proteins of man and pig. J Pharm Pharmacol 1973 Dec; 25 (12): 964-7.
[139] Miller RP, Roberts RJ, Fischer LJ. Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther 1976 Mar; 19 (3): 284-94.
[140] Miner DJ, Kissinger PT. Evidence for the involvement of N-acetyl-p- quinoneimine in acetaminophen metabolism. Biochem Pharmacol 1979 Nov 15; 28 (22): 3285-90.
[141] Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol 1980 Oct; 10 Suppl 2 (): 291S-298S.
[142] Davis M, Simmons CJ, Harrison NG, Williams R. Paracetamol overdose in man: relationship between pattern of urinary metabolites and severity of liver damage. Q J Med 1976 Apr; 45 (178): 181-91.
[143] Prescott LF, Wright N. The effects of hepatic and renal damage on paracetamol metabolism and excretion following overdosage. A pharmacokinetic study. Br J Pharmacol 1973 Dec; 49 (4): 602-13.
[144] Briant RH, Darrington RE, Cleal J, Williams FM. The rate of acetaminophen metabolism in the elderly and the young. J Am Geriatr Soc 1976; 24 (8): 359-61.
[145] Slattery JT, Levy G. Acetaminophen kinetics in acutely poisoned patients. Clin Pharmacol Ther 1979 Feb; 25 (2): 184-95.
[146] Graudins A, Aaron CK, Linden CH. Overdose of extended-release acetaminophen. [Letter] N Engl J Med 1995 Jul 20; 333 (3): 196.
[147] Cetaruk EW, Dart RC, Horowitz RS, Hurlbut KM. Extended-release acetaminophen overdose. [Letter] JAMA 1996 Mar 6; 275 (9): 686.
[148] Gelotte CK, Auiler JF, Lynch JM, Temple AR, Slattery JT. Disposition of acetaminophen at 4, 6, and 8 g/day for 3 days in healthy young adults. Clin Pharmacol Ther 2007 Jun; 81 (6): 840-8.
[149] O'Neill M, editor. The Merck index. 14th ed. Whitehouse Station (NJ): Merck & Co; 2006. p. 9.

Do Not Archive.

This document is current on day of issue,
NZ: 24.Jul.2017

Disclaimer

All information contained on this database is as accurate and up-to-date as our resources allow. Since the University of Otago, the New Zealand National Poisons Centre and Intergen cannot anticipate or control the conditions under which this information may be used, each user should view the information in the specific context of the intended application.

The University of Otago, the New Zealand National Poisons Centre and Intergen will not be responsible for damages of any nature resulting from use or reliance upon this information.

© National Poisons Centre, New Zealand. Portions © Intergen.

If you would like further information about TOXINZ, or wish to make comment, please contact us on +64 3 479 7248 or email us at TOXINZ@otago.ac.nz.